NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
DBV Technologies S.a. DBVT
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.6M
▲ 35.8% vs FY2024
EPS · FY25
$-1.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-149.8%
Net margin · FY25
-2607.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.6M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 2607 cents on every revenue dollar this year.
Per share
USD -1.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-149.8%
Return on equity, FY2025
ROE
Operating margin-2609.2%
Net margin-2607.3%
Return on assets-98.2%
Each USD of equity lost 150 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−13.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.2%
−13.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 233.7M
total assets, end of FY2025
Total assetsUSD 233.7M
EquityUSD 168.8M
CashUSD 194.2M
Current ratio3.67×
Equity funds 72% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.2
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
·
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
Net income $B
−0.1
−0.1
0.1
0.1
−0.1
−0.2
−0.2
EPS, diluted $
−1.05
−1.17
−0.76
−1.24
−1.78
−2.95
−4.65
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−149.8
−136.0
43.5
65.6
−64.2
−80.0
−103.6
Shares out B
·
0.10
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed